Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2006-01-17
2009-12-22
Nickol, Gary B (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S204100, C424S233100
Reexamination Certificate
active
07635485
ABSTRACT:
The present invention relates to genetic vaccines for stimulating cellular and humoral immune responses in humans and other hosts, and, in particular, relates to recombinant viruses that express heterologous antigens of pathogenic viruses, in single dose form.
REFERENCES:
patent: 6544780 (2003-04-01), Wang
patent: 6756523 (2004-06-01), Kahn et al.
patent: 6964762 (2005-11-01), Wang et al.
patent: WO 03/028632 (2003-04-01), None
patent: WO 03/038057 (2003-05-01), None
patent: WO 03/070920 (2003-08-01), None
patent: WO 03/092582 (2003-11-01), None
Cohen, Immunity's yin and yang A successful vaccine must first avoid being eliminated by preexisting immunity before it can promote a protective immune response, IAVI Report, downloaded from http://www.iavireport.org/issues/issues10-1/immunity.asp on Jun. 2, 2008.
Varnavski et al., Preexisting Immunity to Adenovirus in Rhesus Monkeys Fails To Prevent Vector-Induced Toxicity, 2002, Journal of Virology, vol. 76, No. 11, pp. 5711-5719.
Warfield et al., Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge, 2007, Journal of Infectious Diseases, vol. 196, Supplemental 2, pp. S430-S437.
Goodchild, Vaccine for Ebola virus, 2008, EurekAlert, downloaded from http://www.eurekalert.org/pub—releases/2008-03/sfgm-vfe032808.php on Jun. 2, 2008.
Center for Biosecurity, University of Pittsburgh Medical Center, Hemorrhagic Fever Viruses (VHF), 2008 <www.upmc-biosecurity.org.
Sullivan et al.,Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs, 2006, PLoS Medicine, vol. 3, No. 6, pp. 865-873.
Aoki, K. et al. 1999 “Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro.”Mol. Med. 5:224-231.
Chan, S.Y. et al. 2000 “Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses.”J. Gen. Virol. 81:2155-2159.
Feldmann, H. et al. 2003 “Ebola virus: from discovery to vaccine.”Nature Rev. 3:677-685.
Gupta, M. et al. 2001 “Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.”J. Virol. 75:4649-4654.
Hart, M.K. 2003 “Vaccine research efforts for filoviruses.”Int. J. Parasitol. 33:583-595.
Hevey, M. et al. 1998 “Marburg virus vaccines based upon Alphavirus replicons protect guinea pigs and non-human primates.”Virology251:28-37.
Jahrling, P.B. et al. 1996 “Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses.”Arch. Virol. Suppl. 11:135-140.
Jahrling, P.B. et al. 1999 “Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections.”J. Infect. Dis. 179:S224-S234.
Ksiazek, T.G. et al. 1992 “Enzyme .immunosorbent assay for Ebola virus antigens in tissues of infected primates.”J. Clin. Microbiol. 30:947-950.
Ohno, T. et al. 1994 “Gene therapy for vascular smooth muscle cell proliferation after arterial injury.”Science265:781-784.
Parren, P.W.I. et al. 2002 “Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.”J. Virol. 76:6408-6412.
Sanchez, A. et al. 1998 “Biochemical analysis of the secreted and virion glycoproteins of Ebola virus.”J. Virol. 72:6442-6447.
Sullivan, N.J. et al. 2000 “Development of a preventive vaccine for Ebola virus infection in primates.”Nature408:605-609.
Sullivan, N.J. et al. 2003 “Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.”Nature424:681-684.
Takada, A. et al. 2000 “Downregulation of β1 integrins by Ebola virus glycoprotein: implication for virus entry.”Virology278:20-26.
Tang, M. et al. 2002 “Recombinant adenovirus encoding the HA gene from swine H3N2 influenza virus partially protects mice from challenge with heterologous virus: A/HK/1/68 (H3N2).”Arch. Virol. 147:2125-2141.
Tatsis, N. et al. 2004 “Adenoviruses as vaccine vectors.”Mol. Ther. 10:616-629.
Volchkov, V.E. et al. 2001 “Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity.”Science291:1965-1969.
Walsh, P.D. et al. 2003 “Catastrophic ape decline in western equatorial Africa.”Nature422:611-614.
Wesseling, J.G et al. 1993 “Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection.”J. Gen. Virol. 74:2061-2069.
Wilson, J.A. & Hart, M.K. 2001 “Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein.”J. Virol. 75:2660-2664.
Xiang, Z.Q. et al. 1996 “A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.”Virology219:220-227.
Xu, L. et al.1998 “Immunization for Ebola virus infection.”Nature Med. 4:37-42.
Yang, Z.-Y. et al. 2000 “Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.”Nature Med. 6:886-889.
Yang, Z-Y. et al. 2003 “Overcoming immunity to a viral vaccine by DNA priming before vector boosting.”J. Virol. 77:799-803.
Ye, W.W. et al. 1991 “Co-expression of hepatitis B virus antigens by a non-defective adenovirus vaccine vector.”Arch. Virol. 118:11-27.
Chen P., et al., “Effective repeat administration with adenovirus vectors to the muscle”, Gene Therapy (2000) vol. 7, pp. 587-595.
Farina S. F., et al., “Replication-Defective Vector Based on a Chimpanzee Adenovirus”, Journal of Virology, Dec. 2001, vol. 75, No. 23, pp. 11603-11613.
Havenga , M. J. E., et al., “Improved Adenovirus Vectors for Infection of Cardiovascular Tissues”, Journal of Virology, Apr. 2001, vol. 75, No. 7, pp. 3335-3342.
Havenga , M. J. E., et al., “Exploiting the Natural Diversity in Adenovirus Tropism for Therapy and Prevention of Disease”, Journal of Virology, May 2002, vol. 76, No. 9, pp. 4612-4620.
Kass-Eisler, A., et al., “Circumventing the immune response to adenovirus mediated gene therapy”, Gene Therapy (1996), vol. 3, pp. 154-162.
Mastrangeli, A., et al., “Sero-Switch Adenovirus-Mediated in Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype”, Human Gene Therapy, Jan. 1, 1996, vol. 7, pp. 79-87.
Vogels R., et al., “Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity”, Journal of Virology, Aug. 2003, vol. 77, No. 15, pp. 8263-8271.
Geisbert Thomas W.
Jahrling Peter B.
Nabel Gary J.
Sullivan Nancy J.
Blumel Benjamin P
Nickol Gary B
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Method of accelerated vaccination against Ebola viruses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of accelerated vaccination against Ebola viruses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of accelerated vaccination against Ebola viruses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4104513